Phase 1b study of marizomib (MRZ) in combination with temozolomide (Temodar) and radiation in newly diagnosed, Grade 4 malignant glioma

Trial Profile

Phase 1b study of marizomib (MRZ) in combination with temozolomide (Temodar) and radiation in newly diagnosed, Grade 4 malignant glioma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Marizomib (Primary) ; Temozolomide
  • Indications Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Jul 2017 According to Novocure media release,Dr. Roger Stupp is the Principal Investigator of this trial.
    • 24 Jul 2017 The protocol for addtion of new arm for this study to evaluate the safety of marizomib and temozolomide in combination with Optune has been submitted to an institutional review board, and this arm of the trial is expected to open in the third quarter of 2017.
    • 06 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top